<DOC>
	<DOC>NCT00583947</DOC>
	<brief_summary>To determine the safety and tolerability of Arformoterol Tartrate in children with asthma</brief_summary>
	<brief_title>A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects</brief_title>
	<detailed_description>A randomized, double-blind two-way crossover study of three cumulative doses of arformoterol (7.5 ug per nebulization) and levalbuterol (0.63 mg per nebulization) given over a one hour period, followed by a single open-label treatment day with three cumulative doses of arformoterol 15 ug in subjects 2-11 years of age with asthma. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Male and Female Between Age 2 and 11, inclusive, at the time of consent Weight equal to or greater than 15 Kg History of physiciandiagnosed asthma of at least 2 years duration for children age 6 and older, and at least 1 year duration for children 5 and younger. Female subject who is pregnant or lactating. Subject who has a history of hospitalization for asthma within one year, or who is scheduled for inpatient hospitalization, including elective surgery during the course of the trial. Subject with any history of lifethreatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures. Subject with a history of cancer. Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders. Subject with a history of cigarette smoking or use of any tobacco products.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
</DOC>